Publication | Open Access

LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial

Breast OncologyOncologyLba13 Adjuvant RibociclibMedicineClinical TrialsGynecologyAromatasePharmacotherapyBreast CancerCancer TreatmentNatalee Trial4-Year OutcomesPharmacologyRadiation OncologyCancer ResearchEndocrine-related CancerHealth Sciences